A second phase 3 trial is slated for Astra’s CD19 T-cell engager surovatamig.

First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.

Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.

The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.

The ESMO presidential session will feature data from Destiny-Breast05 and 11.

Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.

So who else could be interested in the oestrogen degrader?

The companies clash over survival curve similarities – and differences.

Tolerability could decide first-line therapy in EGFRm disease.